Press releases

Diabetics and other complex patients see strong results with TAXUS stents

Company plans to appeal the judgment of the Delaware U.S. District Court

Details currently confidential; will become public when the European Commission announces its decision

ISS report notes the "compelling strategic rationale" for the combination of companies

Results of the study were published in today's edition of JAMA

Six-month results are consistent with ARRIVE I data

Complex insulin-treated diabetic population shows numerical trend toward improved MACE outcomes with TAXUS versus Cypher

TAXUS trials continue to deliver positive outcomes in complex cases

Team will lead CRM Group following acquisition of Guidant

Completes Company's application for FDA approval

Results highlight efficacy of TAXUS in most complex lesions and highest risk patients

A live webcast and replay of the March 9 conference session will be available

Shareholders of both companies to vote on March 31, 2006

A live webcast and replay of the March 7 conference session will be available

(February 15, 2006) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received reimbursement approval from the French government for its TAXUS

"We reviewed with the FDA a path to resolve the issues they have identified, and we committed to working closely with them to ensure they are resolved," said Tobin

A live webcast and replay of the February 8 conference session will be available

A live webcast and replay of the February 7 conference call will be available

Merger agreement to combine the two companies, creating one of the largest medical technology companies in the world

Study was presented at the Association for Vascular Access (AVA) Annual Conference in Savannah, GA

(January 5, 2006) -- Boston Scientific Corporation (NYSE: BSX) announced today that President and Chief Executive Officer Jim Tobin has agreed to a request from the Board of Directors to extend...

New device pass-through code is only intended for use in the hospital outpatient setting under Medicare

Boston Scientific Corporation (NYSE: BSX) today announced financial results for the year and fourth quarter ended December 31, 2005.

(October 24, 2005) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has acquired a portfolio of proprietary endoscopic stent technologies from Willy Rüsch GmbH (Rüsch), a...

and Washington, D.C. (October 20, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced 30-day safety data from the transitional phase of its OLYMPIA registry. The OLYMPIA registry is...